Publication Topic

Chappell G, Welsh B, Harvey S, Harris M, Wikoff D. Validation and application of a text mining tool in the identification and categorization of mechanistic data: A case study in improving problem formulation of carcinogenicity assessments. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Wikoff DS, Rager J, Harvey S, Haws L, Chappell G, Borghoff S. Framework for quantitative consideration of study quality and relevance in the systematic evaluation of mechanistic data per the Ten Key Characteristics of Carcinogens. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Wikoff D, Borghoff S, Rager J, Harvey S, Haws L. 2016. A systematic review of the mechanistic evidence of tetrabromobisphenol TBBPA as a human carcinogen according to the ten key characteristics of carcinogens (TKCC) identified by Smith et al. (2016). PROSPERO 2016:CRD42016046429.

Borghoff SJ. Organization and review of mechanistic data according to “Ten Key Characteristics of Carcinogens” (TKCC) {Smith et al., 2016}. Presented at the 42^nd Annual Summer Meeting of the Toxicology Forum, Salt Lake City, UT, July 2016.

Panko JM, Benson SM, Kreider ML. Meta-analysis of lung cancer risk related to diesel exposure by occupation and evaluation of exposure response. Abstract #2976. Poster at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

Thompson CM, Bichteler A, Rager JE, Suh M, Proctor DM, Haws LC, Harris MA. 2016. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium. Mut Res/Genet Toxicol Environ Mutagen 800-801(April):28-34; doi: 10.1016/j.mrgentox.2016.01.008. PMID: 27085472.

Petkov P, Patlewicz G, Schultz TW, Honma M, Todorov M, Kotov S, Dimitrov SD, Donner EM, Mekenyan OM. 2015. A feasibility study: Can information collected to classify for mutagenicity be informative in predicting carcinogenicity? Regul Toxicol Pharmacol 72(1):17-25; doi: 10.1016/j.yrtph.2015.03.003. PMID: 25792138.

Thompson CM, Young RR, Suh M, Dinesdurage H, Elbekai R, Harris MA, Rohr AC, Proctor DM. Hexavalent chromium does not induce mutations in the oral mucosa of transgenic Big Blue® rats following drinking water exposures at a carcinogenic dose. Presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

Bhusari S, Malarkey DE, Hong HH, Wang Y, Masinde T, Nolan M, Hooth NJ, Lea IA, Vasconcelos D, Sills RC, Hoenerhoff MJ. 2014. Mutation spectra of Kras and Tp53 in urethral and lung neoplasms in B6C3F1 mice treated with 3,3′,4,4′-tetrachloroazobenzene. Toxicol Pathol 42(3):555–564; doi: 10.1177/0192623313491169. PMID: 23703846.

Proctor DM, Thompson CM, Suh M, Haws LC, Harris MA. 2012. Mode of action for intestinal carcinogenesis of ingested hexavalent chromium in mice. Presented at Society of Toxicology 51st Annual Meeting, San Francisco, CA, March 2012.

Thompson CM, Proctor DM, Suh M, Haws LC, Hebert CD, Mann JF, Shertzer HG, Hixon JG, Harris MA. 2012. Comparison of the effects of hexavalent chromium in the alimentary canal of F344 rats and B6C3F1 mice following exposure in drinking water: Implications for carcinogenic modes of action. Toxicol Sci 125(1):79-90; doi: 10.1093/toxsci/kfr280. PMID: 22011396.

Thompson CM, Haws LC, Harris MA, Gatto NM, Proctor DM. 2011. Application of the U.S. EPA mode of action framework for purposes of guiding future research: A case study involving the oral carcinogenicity of hexavalent chromium. Toxicol Sci 119(1):20-40; doi: 10.1093/toxsci/kfq320. PMID: 20947717.

Naven RT, Louise-May S, Greene N. 2010. The computational prediction of genotoxicity. Exp Opin Drug Metabol Toxicol 6(7):1-11; doi: 10.1517/17425255.2010.495118. PMID: 20528613.

Waters MD, Jackson MA, Lea IA. 2010. Characterizing and predicting carcinogenicity and mode-of-action using conventional and toxicogenomics methods. Mutat Res 705(3):184–200; doi: 10.1016/j.mrrev.2010.04.005.

Proctor DM, Gatto NM, Hong SJ, Allamneni KP. 2007. Mode-of-action framework for evaluating the relevance of rodent forestomach tumors in cancer risk assessment. Toxicol Sci 98(2):313–326; doi: 10.1093/toxsci/kfm075. PMID: 17426108.

Borowsky AD, Dingley KH, Ubick E, Turteltaub KW, Cardiff RD, Devere-White R. 2006. Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model. Neoplasia 8(9):708–715; doi: 10.1593/neo.06373. PMID: 16984728.

Malfatti MA, Dingley KH, Nowell-Kadlubar S, Ubick EA, Mulakken N, Nelson D, Lang NP, et al. 2006. The urinary metabolite profile of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine is predictive of colon DNA adducts after a low-dose exposure in humans. Cancer Res 66(21):10541–10547; doi: 10.1158/0008-5472.CAN-06-1573. PMID: 17079477.

Hays T, Rusyn I, Burns AM, Kennett MJ, Ward JM, Gonzalez FJ, Peters JM. 2005. Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 26(1):219-227; doi: 10.1093/carcin/bgh285. PMID: 15447978.

Chepanoske CL, Brown K, Turteltaub KW, Dingley KH. 2004. Characterization of a peptide adduct formed by N-acetoxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a reactive intermediate of the food carcinogen PhIP. Food Chem Toxicol 42(8):1367–1372; doi: 10.1016/j.fct.2003.11.012. PMID: 15207388.

Mally A, Zepnik H, Wanek P, Eder E, Dingley K, Ihmels H., et al. 2004. Ochratoxin A: Lack of formation of covalent DNA adducts. Chem Res Toxicol 17(2):234–242; doi: 10.1021/tx034188m. PMID: 14967011.